Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
DiaMedica Therapeutics Inc. logo — $DMAC

DiaMedica Therapeutics Inc.

$DMAC

Founded 2000 United States Minneapolis, United States 38 employees Post Ipo Equity Total: $124.95M Biopharma, Biotechnology +1

General Information

Company Name DiaMedica Therapeutics Inc.
Founded Year 2000
Location United States Minneapolis, United States +1
Employees 38
Industries Biopharma, Biotechnology, Health Care
Funding Stage Post Ipo Equity
Social

Get notified when DiaMedica Therapeutics Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. ($DMAC) is a clinical-stage biopharmaceutical company founded in 2000. The company focuses on developing innovative treatments for neurological and kidney diseases, addressing significant unmet clinical needs in these areas where no current therapies are available. DiaMedica operates within the Biopharma, Biotechnology, and Health Care sectors and is headquartered in the United States. The company recently secured a $37.50M Post-IPO Equity investment on 21 June 2023. This investment is a testament to the confidence of investors in DiaMedica's innovative approach and the potential of its treatments. As the company continues to advance its clinical development programs, this funding will play a crucial role in driving research, development, and potential commercialization efforts. With a solid focus on addressing critical medical needs, DiaMedica Therapeutics Inc. is well positioned to make significant strides in the biopharmaceutical industry. The recent investment further underscores the company's potential to bring valuable and groundbreaking treatments to the market, potentially transforming the landscape of neurological and kidney disease therapeutics. For more information, visit www.diamedica.com.

Taxonomy: biopharmaceutical company, clinical-stage, neurological diseases, kidney diseases, chronic kidney disease, acute ischemic stroke, vascular diseases, DM199, recombinant protein, treatments, clinical need, stroke, therapies, innovative treatments

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 21 Jun 2023
Post-IPO Equity •••••• - 18 Apr 2023
Post-IPO Equity •••••• - 27 Sep 2021
Post-IPO Equity •••••• - 10 Aug 2020
Post-IPO Equity •••••• - 13 Feb 2020

View All 10 Funding Rounds

DiaMedica Therapeutics Inc. Alternatives & Competitors

DiaMedica Therapeutics Inc. vs
Unicycive Therapeutics
Unicycive Therapeutics United States

Unicycive Therapeutics delivers life-changing medicines for kidney patients | NASDAQ:UNCY

Post Ipo Equity
24 employees
Biotechnology, Health Care
Compare DiaMedica Therapeutics Inc. vs Unicycive Therapeutics
DiaMedica Therapeutics Inc. vs
Visterra Inc.
Visterra Inc. United States

We bring better biologics to life. Biospace Best Place to Work 2024!

Series C
139 employees
Biotechnology, Health Care
Compare DiaMedica Therapeutics Inc. vs Visterra Inc.
DiaMedica Therapeutics Inc. vs
Dx Biosamples, LLC
Dx Biosamples, LLC United States

Providing the highest quality of human biospecimens to the Global Life Science Community!

7 employees
Biotechnology, Life Sciences
Compare DiaMedica Therapeutics Inc. vs Dx Biosamples, LLC

FAQ About DiaMedica Therapeutics Inc.

$DMAC
DiaMedica Therapeutics Inc. was founded in 2000.
DiaMedica Therapeutics Inc. is headquartered in Minneapolis, United States.
DiaMedica Therapeutics Inc. operates in the following industries: Biopharma, Biotechnology, Health Care.
DiaMedica Therapeutics Inc. has approximately 38 employees.
DiaMedica Therapeutics Inc. has completed 10 funding rounds, raising a total of $124.95M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to DiaMedica Therapeutics Inc. include Unicycive Therapeutics, Visterra Inc., Dx Biosamples, LLC, AM-Pharma, Breye Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
DiaMedica Therapeutics Inc. and Unicycive Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors DiaMedica Therapeutics Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes